Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168694 · ClinicalTrials.gov registry record
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 606
- Enrollment target
NCT07168694: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07168694 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 606 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168694 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 606 participants
- Enrollment target
Study Summary
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2024-09-26 |
What the finished NCT07168694 record still lists
NCT07168694 is an observational study that tracks outcomes without assigning an intervention. The registered 606 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07168694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07168694 about?
NCT07168694 is a clinical study titled "A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia". The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multipl...
What is the current status of trial NCT07168694?
This trial is currently completed. The enrollment target is 606 participants. The study started on 2024-04-16. Estimated completion is 2024-09-26.
Who is sponsoring clinical trial NCT07168694?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI